Eli Lilly and Company’s emblem is displayed throughout a press convention in Houston, Texas, U.S., Sept. 23, 2025.
Antranik Tavitian | Reuters
Eli Lilly mentioned on Tuesday it could purchase Centessa Pharmaceuticals in a deal valued at up to $7.8 billion because the U.S. drugmaker appears to diversify past its metabolic portfolio and develop into therapies for sleep issues.
UK-based Centessa is creating therapies for extreme daytime sleepiness and different neurological situations. Its lead remedy is presently in mid-stage research for narcolepsy or extreme daytime sleepiness.
Lilly has provided $38 per share in money, a premium of 37.8% to Centessa’s U.S.-listed inventory’s final shut. Centessa’s U.S.-listed shares jumped 46% in premarket buying and selling.
Lilly has additionally provided one non-transferable contingent worth proper (CVR) of about $9 per share, or value about $1.5 billion.
Centessa’s pipeline consists of extra medical and preclinical-stage therapies with potential to deal with a broader vary of neurological and neuropsychiatric situations, the businesses mentioned.
The deal is predicted to shut in the third quarter.
Eli Lilly, which touched a trillion-dollar valuation final yr on the success of its blockbuster weight-loss therapies, has been making sizable investments to bolster different elements of its pipeline.
This yr, the corporate has spent $2.4 billion to purchase Orna Therapeutics to develop its next-generation cell remedy capabilities, and greater than $1 billion to purchase autoimmune drug developer Ventyx Biosciences.
